Literature DB >> 20827160

Is Kaposi's sarcoma occurring at higher CD4 cell counts over the course of the HIV epidemic?

Nancy F Crum-Cianflone1, Katherine Huppler Hullsiek, Anuradha Ganesan, Amy Weintrob, Jason F Okulicz, Brian K Agan.   

Abstract

We evaluated longitudinal rates of Kaposi's sarcoma and trends in CD4 cell counts at the time of Kaposi's sarcoma diagnosis during the HIV epidemic (1985-2008). Although rates of Kaposi's sarcoma have decreased, cases are now occurring at higher CD4 cell counts over time, with more than one-third of cases diagnosed in 2002-2008 occurring at CD4 cell counts of at least 350 cells/μl. These data support future studies evaluating the impact of highly active antiretroviral therapy initiation at higher CD4 cell counts to further reduce Kaposi's sarcoma.

Entities:  

Mesh:

Year:  2010        PMID: 20827160      PMCID: PMC2978255          DOI: 10.1097/QAD.0b013e32833f9fb8

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  18 in total

1.  Development of Kaposi's sarcoma despite sustained suppression of HIV plasma viremia.

Authors:  J Chan; S Kravcik; J B Angel
Journal:  J Acquir Immune Defic Syndr       Date:  1999-10-01       Impact factor: 3.731

2.  Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma.

Authors:  Guglielmo Nasti; Ferdinando Martellotta; Massimiliano Berretta; Maurizio Mena; Marco Fasan; Giovanni Di Perri; Renato Talamini; Gabriella Pagano; Maria Montroni; Roberta Cinelli; Emanuela Vaccher; Antonella D'Arminio Monforte; Umberto Tirelli
Journal:  Cancer       Date:  2003-12-01       Impact factor: 6.860

3.  Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy.

Authors:  Elizabeth Connick; Madeleine A Kane; Irene E White; John Ryder; Thomas B Campbell
Journal:  Clin Infect Dis       Date:  2004-11-19       Impact factor: 9.079

4.  Suspected immune reconstitution inflammatory syndrome associated with the proliferation of Kaposi's sarcoma during HAART.

Authors:  Ramesh V Nathan
Journal:  AIDS       Date:  2007-03-30       Impact factor: 4.177

5.  Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy.

Authors:  James H Gallafent; Susan E Buskin; Peter B De Turk; David M Aboulafia
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

6.  Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.

Authors:  C Lebbé; L Blum; C Pellet; G Blanchard; O Vérola; P Morel; O Danne; F Calvo
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

7.  Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion.

Authors:  S K Brodine; R A Shaffer; M J Starkey; S A Tasker; J L Gilcrest; M K Louder; A Barile; T C VanCott; M T Vahey; F E McCutchan; D L Birx; D D Richman; J R Mascola
Journal:  Ann Intern Med       Date:  1999-10-05       Impact factor: 25.391

8.  Trends in cancer risk among people with AIDS in the United States 1980-2002.

Authors:  Eric A Engels; Ruth M Pfeiffer; James J Goedert; Phillip Virgo; Timothy S McNeel; Steven M Scoppa; Robert J Biggar
Journal:  AIDS       Date:  2006-08-01       Impact factor: 4.177

9.  The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study.

Authors:  Amanda Mocroft; Ole Kirk; Nathan Clumeck; Panaglotis Gargalianos-Kakolyris; Hanna Trocha; Nelly Chentsova; Francisco Antunes; Hans-Jürgen Stellbrink; Andrew N Phillips; Jens D Lundgren
Journal:  Cancer       Date:  2004-06-15       Impact factor: 6.860

10.  Spectrum of disease in persons with human immunodeficiency virus infection in the United States.

Authors:  K M Farizo; J W Buehler; M E Chamberland; B M Whyte; E S Froelicher; S G Hopkins; C M Reed; E D Mokotoff; D L Cohn; S Troxler
Journal:  JAMA       Date:  1992-04-01       Impact factor: 56.272

View more
  9 in total

Review 1.  Impact of antiretroviral therapy on the incidence of Kaposi's sarcoma in resource-rich and resource-limited settings.

Authors:  Aggrey S Semeere; Naftali Busakhala; Jeffrey N Martin
Journal:  Curr Opin Oncol       Date:  2012-09       Impact factor: 3.645

Review 2.  Diagnosis and management of lymphomas and other cancers in HIV-infected patients.

Authors:  Antonino Carbone; Emanuela Vaccher; Annunziata Gloghini; Liron Pantanowitz; Akin Abayomi; Paolo de Paoli; Silvia Franceschi
Journal:  Nat Rev Clin Oncol       Date:  2014-03-11       Impact factor: 66.675

3.  Severe Kaposi Sarcoma in an Urban Public Hospital.

Authors:  Shirin Elisha Kasturia; Clifford Gunthel; Cheng Zeng; Minh Ly Nguyen
Journal:  AIDS Res Hum Retroviruses       Date:  2017-01-31       Impact factor: 2.205

4.  Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada.

Authors:  Robert Dubrow; Li Qin; Haiqun Lin; Raúl U Hernández-Ramírez; Romain S Neugebauer; Wendy Leyden; Keri N Althoff; Chad J Achenbach; Nancy A Hessol; Sharada P Modur; Gypsyamber DʼSouza; Ronald J Bosch; Surbhi Grover; Michael A Horberg; Mari M Kitahata; Angel M Mayor; Richard M Novak; Charles S Rabkin; Timothy R Sterling; James J Goedert; Amy C Justice; Eric A Engels; Richard D Moore; Michael J Silverberg
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-01       Impact factor: 3.731

5.  Oral Kaposi Sarcoma in two patients living with HIV despite sustained viral suppression: New clues.

Authors:  Clement Messeca; Matthieu Balanger; Florent Geoffroy; Xavier Duval; Mahtab Samimi; Sarah Millot
Journal:  J Clin Exp Dent       Date:  2022-05-01

6.  New onset of kaposi sarcoma in a human immunodeficiency virus-1-infected homosexual man, despite early antiretroviral treatment, sustained viral suppression, and immune restoration.

Authors:  Amrei von Braun; Dominique L Braun; Jivko Kamarachev; Huldrych F Günthard
Journal:  Open Forum Infect Dis       Date:  2014-04-17       Impact factor: 3.835

7.  Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi's Sarcoma Patients.

Authors:  Salum J Lidenge; For Yue Tso; Yasaman Mortazavi; John R Ngowi; Danielle M Shea; Julius Mwaiselage; Charles Wood; John T West
Journal:  Cancers (Basel)       Date:  2020-06-16       Impact factor: 6.639

8.  Selected genes of Human herpesvirus-8 associated Kaposi's sarcoma among patients with Human Immunodeficiency Virus-1 and Acquired Immunodeficiency Disease Syndrome.

Authors:  Rodgers Norman Demba; Nathan Shaviya; Sylviah Mweyeli Aradi; Walter Mwanda
Journal:  Pan Afr Med J       Date:  2019-04-30

9.  Pulmonary Kaposi's sarcoma as the initial presentation of human immunodeficiency virus infection.

Authors:  Tasnim F Imran; Ziyaad Al-Khateeb; Jin Jung; Stephen Peters; Lisa L Dever
Journal:  IDCases       Date:  2014-10-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.